Biography

Prof. Xueying Sun

Harbin Medical University, China


Email: [email protected]


Qualifications


1994 Ph.D., Shandong University, China, Medical Science

1989 B.Sc., Shandong University, China, Medicine


Publications (selected)

  1. Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, Krissansen GW, Qiao H, Sun X. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. FEBS J. 2013 Oct 24. doi: 10.1111/febs.12577.
  2. Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, Zhang Q, Wu Y, Jiang H, Sun X. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cellular Signalling 2013;25:931-938. doi: 10.1016/j.cellsig.2013.01.011. IF: 4.2.
  3. Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F, Wei Z, Zhai B, Kanwar JR, Jiang H, Li J, Sun X. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci 2013;104:375-82. doi: 10.1111/cas.12088. IF: 3.3.
  4. Wei Z, Jiang X, Liu F, Qiao H, Zhou B, Zhai B, Zhang L, Zhang X, Han L, Jiang H, Krissansen GW, Sun X. Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo. Tumor Biolgy 2013;34:181-92. doi: 10.1007/s13277-012-0527-8.  IF:2.4.
  5. He C, Sun XP, Qiao H, Jiang X, Wang D, Jin X, Dong X, Wang J, Jiang H, Sun X. Downregulating Hypoxia-inducible factor-2α improves the efficacy of doxorubicin to treat hepatocellular carcinoma. Cancer Science 2012; 103: 528-534. (doi: 10.1111/j.1349-7006.2011.02177.x). Corresponding author. IF: 3.3.
  6. Kanwar JR, Sun X, Punj V, Sriramoju B, Mohan RR, Zhou SF, Chauhan A, Kanwar RK. Nanoparticles in the treatment and diagnosis of neurological disorders: Untamed dragon with fire power to heal. Nanomedicine 2012;8:399-414. doi:10.1016/j.nano.2011.08.006 IF: 6.4.
  7. Wang D, Ma Y, Li Z, Kang K, Sun X, Pan S, Wang J, Pan H, Liu L, Liang D, et al. The role of AKT1 and autophagy in the protective effect of hydrogen sulphide against hepatic ischemia/reperfusion injury in mice. Autophagy 2012; 8(6):954-962. IF: 7.4.
  8. Wang J, Ma Y, Jiang H, Zhu H, Liu L, Sun B, Pan S, Krissansen GW, Sun X Overexpression of von Hippel-Lindau enhances the efficacy of doxorubicin to suppress hepatocellular carcinoma by downregulating HIFα and inhibiting NF-κB activity in mice. Journal of Hepatology 2011;55:359-368. doi: 10.1016/j.jhep.2010.10.043. Impact Factor: 9.3, Corresponding Author.
  9. Ma L, Qiao H, He C, Yang Q, Cheung CH, Kanwar JR, Sun X. Modulating interaction of CXCR4 and SDF-1α by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Investigational New Drugs 2012;30(2):508-17. doi: 10.1007/s10637-010-9578-0. Impact Factor: 3.072, Corresponding Author.
  10. Gao Y, Yao X, Zhang Y , Li W, Kang K, Sun L, Sun X. The protective role of hydrogen sulfide in cardiac ischemia reperfusion-induced injury in diabetic rats. International Journal of Cardiology 2011;152:177-83. doi:10.1016/j.ijcard.2010.07.012. Impact Factor: 6.496, Corresponding Author.
  11. Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, Sun X, Jiang H. Genistein potentiates the effect of ATO against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Letters. 2011;301:75-84. Impact Factor: 3.741.
  12. Sun L, Shi T, Qiao H, Jiang X, Jiang H, Krissansen GW, Sun X Hepatic Overexpression of Heme Oxygenase-1 Improves Liver Allograft Survival by Expanding T Regulatory Cells. Journal of Surgical Research 2011;166:e187–e194. doi:10.1016/j.jss.2010.11.917. Impact Factor: 2.176, Corresponding Author.
  13. Zhang F, Mao Y, Qiao H, Jiang H, Tong L, Sun X. Protective effects of taurine against endotoxin-induced acute liver injury after hepatic ischemia reperfusion. Amino Acids 2010;38:237-245. Impact Factor: 3.877, Corresponding Author.
  14. Jiang H, Ma Y, Chen X, Pan S, Sun B, Krissansen GW, Sun X. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cancer Science 2010;101:975-983. Impact Factor: 3.77, Corresponding Author.
  15. Gu Y, Guise CP, Patel K, Holford SD, Abbattista MR, Li J, Sun X, Atwell GJ, Boyd M, Patterson AV, Wilson WR. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol 2011;67:543-555. DOI 10.1007/s00280-010-1354-5. Impact Factor: 2.654.
  16. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S, Krissansen GW, Sun X. Downregulation of nuclear factor-kB P65 subunit by small interfering RNA synergizes with gemcitabine to treat pancreatic cancer. Cancer Letters 2010;291:90-98. Impact Factor: 3.741, Corresponding Author.
  17. Sun X, Vale M, Jiang X, Gupta R, Krissansen GW. Antisense HIF-1 prevents acquired tumour resistance to the anti-angiogenic drug angiostatin. Cancer Gene Therapy 2010;17:532-40. Impact Factor: 3.126.
  18. Cheung CH, Sun X, Kanwar JR, Bai JZ, Cheng L, Krissansen GW. A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell International 2010;10:36 doi:10.1186/1475-2867-10-36. Impact Factor: 2.03.
  19. Sun X, Jiang H, Jiang X, Tan H, Meng Q, Sun B, Xu R, Krissansen GW. Downregulating hypoxia-inducible factor 1 augments transcatheter arterial embolization to treat hepatocellular carcinomas in rats. Human Gene Therapy 2009;20:314-324. Impact Factor: 4.202, Corresponding Author.
  20. Kanwar JR, Kanwar RK, Sun X, Punj V, Matta H, Morley SM, Parratt A, Puri M, Sehgal R. Molecular and biotechnological advances in milk proteins in relation to human health. Current Protein & Peptide Science 2009;10:308-338. Impact Factor: 3.854.
  21. Jiang X, Li H, Qiao H, Jiang H, Xu R, Sun X. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Science 2009; 100:2226-2233. Impact Factor: 3.771, Corresponding Author.
  22. Kang K, Zhao M, Jiang H, Tan G, Pan S, Sun X. The role of hydrogen sulfide in hepatic ischemia reperfusion-induced injury in rats. Liver Transplantation. 2009;15:1306-1314. Impact Factor: 3.724, Corresponding Author.
  23. Wang Y, Meng Q, Qiao H, Jiang H, Sun X. The role of spleen in cyclophosphamide-induced hematosuppression and extramedullary hematopoiesis in mice. Archives of Medical Research 2009;40:249-255. Impact Factor: 1.884，Corresponding Author.
  24. Kanwar JR, Palmano KP, Sun X, Kanwar RK, Gupta R, Haggarty N, Rowan A, Ram S, Krissansen GW. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunology and cell biology2008;86:277-88. Impact Factor: 4.2.
  25. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW, Sun X. Antisense hypoxia-inducible factor 1 α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Science2008;99: 2055-2061. Impact Factor: 3.771, Corresponding Author.
  26. Tse LY, Sun X, Jiang H, Dong X, Chu KW, Xu R. Adeno-associatedvirus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. Journal of Gene Medicine.
  27. Ma L, Luo L, Qiao H, Dong X, Pan S, Jiang H, Krissansen GW, Sun X. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. Journal of Hepatology 2007;46:98-106. Impact Factor: 7.818, Corresponding Author.
  28. Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Sun X. Anti-angiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. International Journal of Cancer 2007;121:416-424. Impact Factor: 4.722, Corresponding Author.
  29. Liu F, Tan G, Li J, Dong X, Jiang H, Krissansen GW, Sun X. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Science 2007;98:1381-1387. Impact Factor: 3.771, Corresponding Author.
  30. Jiang H, Meng F, Li W, Tong L, Qiao H, Sun X. Splenectomy ameliorates acutemultiple organ damage induced by liver warm ischemia reperfusion in rats. Surgery2007;141:32-40. Impact Factor: 3.603, Corresponding Author.
  31. Luo L, Qiao H, Meng F, Dong X, Zhou B, Jiang H, Kanwar JR, Krissansen GW, Sun X. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. International Journal of Cancer 2006;118:1823-1830. Impact Factor: 4.722, Corresponding Author.
  32. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Science2006;97:675-681. Impact Factor: 3.771, Corresponding Author.
  33. Sun X, Krissansen GW, Fung PWC, Xu S, Juan S, Man K, Fan ST, Xu R. Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. International Journal of Cancer 2005;113:670-677. Impact Factor: 4.722.
  34. Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, XuR, and Krissansen GW. Intramuscular delivery of anti-angiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Therapy 2005;12:35-45. Impact Factor: 3.126, Corresponding Author.
  35. Xu R, Sun X (co-first author), Chan D, Tse LY, Xu S, Xiao W, Kung HF, Krissansen GW, Fan ST. Long-term expression of angiostatin suppresses metastatic liver cancer in mice.Hepatology 2003;37:1451-1460. Impact Factor: 10.84.
  36. Sun X, Kanwar JR, Leung E, Vale M, Krissansen GW. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha. Gene Therapy2003;10:2081-2089. Impact Factor: 4.745.
  37. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse B7-H3induces antitumor immunity. Gene Therapy 2003;10:1728-1734. Impact Factor: 4.745.
  38. Sun X, Qiao H, Shi J, Kanwar JR and Krissansen GW. b7 integrins contribute toskin graft rejection. Transplantation 2002; 74 :1202-1203. Impact Factor: 3.498.
  39. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001;8:638-645. Impact Factor: 4.745.
  40. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Therapy 2001; 8:719-727. Impact Factor: 3.126.
  41. Sun X, Zhang J, Gupta R, MacGibbon A, Krissansen GW. Dairy milk fat augments  paclitaxel therapy to suppress tumour metastasis and protects against its side-effects in mice. Clinical & Experimental Metastasis 2011;28(7):675-88. Impact Factor: 3.910.
  42. Sun X, Zhang J, MacGibbon AKH, Black P, Krissansen GW. Bovine milk fat enriched in conjugated linoleic and vaccenic acids attenuates allergic dermatitis in mice. Clin Exp Allergy 2011;41:729-38. doi: 10.1111/j.1365-2222.2011.03723.x. Impact Factor: 4.084.
  43. Tan G, Pan S, Li J, Dong X, Kang K, Zhao M, Jiang X, Kanwar JR, Qiao H, Jiang H, Sun X. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. PLoS ONE 2011; 6: e25943. Corresponding Author.
  44. Sun X, Jiang R, Przepiorski A, Reddy S, Palmano KP, Krissansen GW. “Iron-saturated” bovine lactoferrin improves tamoxifen therapy in the treatment of breast cancer. BMC Cancer. 2012 Dec 11;12:591. doi: 10.1186/1471-2407-12-591. IF: 3.0.
  45. Montrose K, Yang Y, Sun X, Wiles S, Krissansen GW. Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs. Sci Rep. 2013;3:1661. doi: 10.1038/srep01661.
  46. Zhai B, Sun X. Mechanisms of resistance to sorafenib and the strategies in hepatocellular carcinoma. World Journal of Hepatology 2013;5(7): 345-352.
  47. Bo Zhai, Fengli Hu, Xian Jiang, Jun Xu, Dali Zhao, Shangha Pan, Xuesong Dong, Gang Tan, Zheng Wei, Haiquan Qiao, Hongchi Jiang, Xueying Sun. Inhibition of Akt reverses the acquired resistance to sorafenib by inducing autophagic cell death in hepatocellular carcinoma. Cancer Molecular Therapeutics (Under revision).
  48. Dali Zhao, Bo Zhai, Changjun He, Xian Jiang, Shangha Pan, Xuesong Dong, Zheng Wei,  Lixin Ma, Haiquan Qiao, Hongchi Jiang, Xueying Sun. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cellular Signalling (under revision).
  49. Xiaofeng Dong, Xuesong Dong, Peng Xiu, Zongzhen Xu, Bo Zhai, Feng Liu, Hongchi Jiang, Xueying Sun, Jie Li, Haiquan Qiao. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways. PLos one (under revision).
SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top